AVDL
Avadel Pharmaceuticals plc
$21.36
-$0.03(-0.14%)
53
Overall
40
Value
66
Tech
55
Quality
Market Cap
$2.08B
Volume
1.26M
52W Range
$6.38 - $23.57
Target Price
$20.56
Company Overview
| Mkt Cap | $2.08B | Price | $21.36 |
| Volume | 1.26M | Change | -0.14% |
| P/E Ratio | -42.6 | Open | $21.38 |
| Revenue | $169.1M | Prev Close | $21.39 |
| Net Income | $-48.8M | 52W Range | $6.38 - $23.57 |
| Div Yield | N/A | Target | $20.56 |
| Overall | 53 | Value | 40 |
| Quality | 55 | Technical | 66 |
No chart data available
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Sector: Healthcare
Industry: Biotechnology
Latest News
Avadel Pharmaceuticals Acquisition Moves Forward with HSR Expiry
TipRanks Auto-Generated Newsdesk•4 days ago
Avadel Pharmaceuticals (AVDL) Gets a Hold from Wells Fargo
TipRanks Auto-Generated Intelligence Newsdesk•24 days ago
Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL) and Oncolytics Biotech (ONCY)
Catie Powers•25 days ago
Avadel Pharmaceuticals Amends Agreement with Alkermes
TipRanks Auto-Generated Newsdesk•25 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AVDL | $21.36 | -0.1% | 1.26M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Avadel Pharmaceuticals plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW